AKT1 and ovarian cancer: Research conducted by Xu J et al. and Zhi W et al., involving ovarian cancer cell lines and animal models, provides empirical evidence that inhibiting the AKT signaling pathway, either through AKT inhibitors or by subjecting cells to nutrient deprivation, significantly enhances the sensitivity of ovarian cancer cells to PARPi.